Strategic Alliances (Details) - USD ($) $ in Thousands						1 Months Ended		3 Months Ended			9 Months Ended		12 Months Ended	93 Months Ended
	Sep. 14, 2021	Jul. 06, 2021	Jun. 18, 2021	May 05, 2020	Oct. 21, 2019	May 31, 2016	Jan. 31, 2015	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Sep. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues								$ 179,744		$ 385,813	$ 818,856	$ 1,373,387
Milestone revenue recognized											73
LeaderMed | LeaderMed Joint Venture | Corporate Joint Venture
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Ownership interest in joint venture (as a percent)	47.00%
Initial investment in joint venture	$ 11,000
Ownership percentage by related parties (as a percent)	53.00%
CAMP4
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment (in shares)		3,373,008
Outstanding shares (as a percent)		9.00%
Period following first commercial sale in a country		10 years
Nicoya
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment from development and license agreement			$ 5,000
Proceeds including accrued interest for delayed payment			2,500
Proceeds from submission of investigational new drug			$ 2,500
Period after first commercial sale			10 years
Initial upfront payment												5,000
Pfizer | Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum milestone payments							$ 275,000
Milestone payments									$ 85,000
Annual height velocity at point in time					12 months
Initial upfront payment							295,000
Additional milestone payment							275,000
Milestone revenue recognized														$ 85,000
Minimum | Pfizer | Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments							20,000
Maximum | Pfizer | Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments							$ 90,000
Phase Three Initiation | Nicoya
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment from development and license agreement			$ 5,000
Regulatory and Development | Nicoya
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment from development and license agreement			$ 115,000
Transfer of intellectual property and other
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues								4,500		8,768	97,659	22,585
Transfer of intellectual property and other | Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues				$ 3,000
Transfer of intellectual property and other | LeaderMed | LeaderMed Joint Venture | Corporate Joint Venture
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues	$ 1,000												$ 1,000
Transfer of intellectual property and other | LeaderMed | Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues												1,000
Transfer of intellectual property and other | CAMP4
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues		$ 1,500
Transfer of intellectual property and other | CAMP4 | Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues												4,900
Transfer of intellectual property and other | VFMCRP | Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues											3,000
Transfer of intellectual property and other | Pfizer | Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues								2,200		2,500	6,800	8,100
Maximum milestone payments											85,000
Dravet Syndrome Products | CAMP4
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development milestone payments		3,500
Sales milestone payments		$ 90,000
Development milestone payments (in shares)		5,782,299
Non-Dravet Syndrome Products | CAMP4
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development milestone payments		$ 4,000
Sales milestone payments		$ 90,000
Development milestone payments (in shares)		1,082,248
Products
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues								$ 32,388		$ 36,882	$ 104,938	$ 106,490
Regulatory Milestones | EirGen Pharma Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum milestone payments				17,000
Sales Milestones | EirGen Pharma Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum milestone payments				$ 207,000
Exclusive Option | VFMCRP
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum milestone payments						$ 555,000